- Approximately 5-10% of individuals do not respond to GLP-1 drugs.
- The Guardian seeks personal accounts from those who found GLP-1 treatments ineffective.
- Stories will cover various reasons for non-response and alternative approaches.
Understanding GLP-1 Drugs
GLP-1 (glucagon-like peptide-1) drugs, such as Wegovy and Mounjaro, are widely prescribed to manage type 2 diabetes. However, about 5-10% of people do not experience the desired benefits from these medications.
The Guardian is soliciting personal narratives from individuals who have tried GLP-1 drugs but found them ineffective. These stories are crucial in understanding why some patients do not respond to the treatment and in exploring alternative methods.
Reasons for Non-Response
Those sharing their experiences should consider discussing various factors that contributed to the lack of efficacy, such as unbearable side effects or no observable benefits over an extended period. Additionally, stories about encountering stigma due to non-response can provide valuable insights. Another individual mentioned the challenges faced when his colleagues and friends made comments about his condition, which he found embarrassing and demotivating.
Exploring Alternative Approaches
The Guardian encourages contributors to also share their experiences with alternative treatments they have tried in hopes of achieving the health outcomes they were seeking from GLP-1 drugs. These accounts could offer guidance and support to others facing similar challenges.
Note for Submissions
If you're having trouble using the form, click here. To read the terms of service or privacy policy, please visit their respective pages: terms of service here and privacy policy here.
By sharing your story, you can help contribute to a better understanding of the challenges faced by those with type 2 diabetes and support ongoing research into more effective treatments.
Source: The Guardian
Science Daily
153 posts
-
Morning Skywatch: Catch Mercury's Best Show of the YearThis week offers an exceptional opportunity to observe Mercury, which reaches its greatest western elongation on Sunday. Binoculars can aid in spotting the small planet, but caution must be exercised before sunrise.
-
SpaceX Delivers Strong Revenue Growth but Faces Profitability ConcernsSpaceX reported a 92% increase in second-quarter revenue, but the company remains unprofitable and faces ongoing investor concerns.
-
Mathematical Genius Alex Chui Solves Complex PuzzleBritish student Alex Chui breaks records at the International Mathematical Olympiad with perfect scores and proposes a complex puzzle.
-
SpaceX Reports Strong Q2 Earnings Despite Stock DeclineSpaceX reported stronger-than-expected revenue but still faces significant challenges as its stock plummets post-IPO. Despite progress on key projects, investors remain uncertain about the company's long-term financial prospects.
-
Revolutionary Telescope Unveils Sun's Mysteries in Never-Before-Seen DetailNew observations from the Inouye solar telescope provide unprecedented detail of the sun's surface, including swirling vortices that could explain coronal heating and solar flares.
-
SpaceX Rocket Stage Crashes Into Moon: A Rare Incident of Lunar ImpactA four-tonne piece of a discarded SpaceX rocket crashed into the moon at high speed, creating a new lunar crater and posing no danger to Earth.
-
Mathematical Puzzler: Exploring Grid PossibilitiesA mathematical puzzle involving filling a 3×3 grid with numbers such that each row and column multiplies to 30, revealing the importance of prime factors in solving it.
-
Study Reveals Link Between Early Social Media Use and Lower School PerformanceA study finds that children who start using social media early tend to perform worse academically, suggesting a link between constant smartphone use and educational development.
-
UK Science Funding Cuts Spark Concerns About Global StandingCritics argue that recent funding cuts in UK science could harm global standing and stunt research advancements.
-
British Science Funding Crisis Sparks Wide-Spread ConcernLetters from readers and experts critique the decision to cut science funding in Britain, emphasizing the potential long-term damage on research and innovation.
